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At a Glance Commentary 
Scientific knowledge on the subject 
Smoking is a major trigger of Chronic Mucus Hypersecretion (CMH) commonly considered to 
identify a COPD phenotype associated with poor clinical outcomes and hypothesized to be a 
feature of developing COPD.  However, how the relationships between smoking, CMH and 
airway disease develop across adult life is poorly understood. 
 
What this adds to the field 
We provide evidence of an evolving relationship between smoking and CMH during middle-
age suggestive of an early developmental phase of COPD.  We show the course of CMH 
across adult life is more dynamic than previously appreciated, that smoking cessation at any 
age avoids and/or reverses CMH development and that the longer CMH is present the 
greater the FEV1 loss.  These findings suggest the course of CMH reflects that of airway 
disease activity. 
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ABSTRACT 
 
RATIONALE:  Chronic Mucus Hypersecretion (CMH) is common amongst smokers and is 
associated with Chronic Obstructive Pulmonary Disease (COPD) development and 
progression.  Understanding how the relationships between smoking, CMH and COPD 
develop during adult life could facilitate earlier disease detection and intervention. 
METHODS:  We analysed data on CMH, smoking and lung function prospectively collected 
by the MRC National Survey of Health and Development, a nationally representative British 
cohort followed since birth in 1946.  We analysed the longitudinal relationships between 
smoking and CMH, how symptoms during life related to airflow limitation at 60-64 years and 
how CMH duration between ages 43 to 60-64 years related to concurrent FEV1 decline. 
RESULTS:  From 5362 individuals enrolled at birth, 4427 contributed data between ages 20 
and 64 years (52% male, 63% ever-smoker).  Amongst smokers CMH prevalence escalated 
between ages 36 and 43 from 7.6±2.0% to 13.0±2.6%.  At these ages symptoms were 
associated with a higher risk of subsequent airflow limitation (OR (95%CI): 3.70(1.62-8.45); 
4.11(1.85-9.13) respectively).  Across adult life, CMH followed a dynamic remitting-relapsing 
course.  Symptom prevalence following smoking cessation returned to levels seen amongst 
never-smokers.  The longer CMH was present across 3 occasions (ages 43, 53 and 60-64 
years), the greater the concurrent FEV1 decline, corresponding to an additional decrement 
of 3.6±2.5ml/year per occasion that CMH was present (p=0.005). 
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CONCLUSIONS: CMH amongst middle-aged smokers represents an early developmental 
phase of COPD.  Smoking-related CMH usually resolves following smoking cessation but the 
longer its duration the greater the FEV1 lost, suggesting the course of CMH across adult life 
may reflect the underlying course of airway disease activity. 
 
Abstract Word Count: 260 
Keywords:  Chronic Mucus Hypersecretion; Chronic Bronchitis; COPD; Smoking; Cough 
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INTRODUCTION: 
Chronic Mucus Hypersecretion (CMH), also known as chronic bronchitis, is a common 
symptom amongst smokers (1-4).   In those with chronic obstructive pulmonary disease 
(COPD), CMH is associated with more frequent exacerbations (5, 6), steeper lung function 
decline (7), more frequent hospitalisations (7) and higher mortality (8, 9) whilst in smokers 
without COPD, CMH may reflect greater susceptibility to COPD development (4, 10, 11). 
CMH prevalence generally increases with age (1, 12).  However, several longitudinal studies 
have suggested symptom presence within individuals fluctuates over time (1-3, 7, 10, 13)  
influenced, for example, by changing smoking behaviour (1, 2).  Although behavioural, 
genetic and environmental factors acting throughout life may influence COPD development 
(14, 15), most longitudinal studies of symptoms have been relatively short in duration and 
consequently, how the relationship between CMH and smoking develops across adult life 
remains unknown.  Understanding this longitudinal relationship and its association with 
both COPD presence in later life and lung function decline across life may facilitate both 
earlier disease detection, focussed smoking cessation and the development of novel 
interventions. 
Some studies have defined CMH as chronic sputum expectoration (1, 16-18) and others as 
chronic sputum expectoration with chronic cough (7, 19).  However, few studies have 
directly compared the clinical associations of chronic sputum, chronic cough and chronic 
sputum concurrent with chronic cough, making comparisons of reported results difficult 
(20). 
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Using data from the Medical Research Council (MRC) National Survey of Health and 
Development (NSHD) we sought to determine (1) how the relationship between CMH and 
smoking evolves across adult life; (2) to what extent symptoms at different stages of life 
identify those smokers more likely to have airflow limitation (a cardinal feature of COPD) in 
later life; and (3) if CMH duration represents an indicator of concurrent FEV1 decline 
independent of smoking. 
Some of the results of this study have been previously reported in the form of abstracts (21-
25). 
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METHODS:  
 
Population studied 
The NSHD is a study of 5362 individuals, representative of all single births to married women 
during one week in March 1946 within England, Scotland and Wales (26).  Prospective data 
have been collected regularly from this nationally representative cohort of men and women 
since birth. The most recent data collection was completed in 2006-2011 when study 
members reached 60 to 64 years of age.  At this follow up, the 2856 participants still alive 
and with a known current address in mainland Britain were invited for assessment at one of 
six clinical research facilities; those unable or unwilling to travel were offered a home visit 
by a research nurse (27). Invitations were not sent to those who had died (n=778), were 
living abroad (n=570), had previously withdrawn from the study (n=594) or had been lost to 
follow-up (n=564). A total of 2,229 participants (78%) underwent assessment: 1690 
attended the clinical research facility and the remaining 539 were seen in their homes.  The 
participating sample remains broadly representative of native born British men and women 
of the same age (28).  Previously, at ages 36, 43 and 53, study members were interviewed 
and examined in their own homes by a team of trained research nurses. 
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Data: 
Responses to the MRC respiratory symptom questionnaire (16, 17, 29) were recorded at 20, 
25, 36, 43, 53 and 60-64 years of age at the nurse-led interviews or via postal 
questionnaires.  At each age whether participants were smoking and the number of 
cigarettes they smoked per day was recorded.  Self-rolled cigarettes were converted as 
follows: 1oz tobacco=25 manufactured cigarettes. At ages 36, 43, 53 and 60-64 years, 
individuals were asked if they had ever previously smoked one or more cigarettes daily for 
one or more years.  At 20 years of age previous smoking behaviour was recorded.  Pre-
bronchodilator lung function was measured at 43, 53 and 60-64 years supervised and 
quality assessed by trained nurses.  The same Micro Medical Plus turbine electronic 
spirometer models were used on each occasion.  Three manoeuvres were recorded in 1989 
and two in 1999 and 2006-2011 but otherwise the same protocol, developed prior to the 
publication of the current ATS/ERS guidelines (30), was followed at each visit.  The largest of 
two reproducible readings, defined as within 150 millilitres of each other, of forced 
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) was used in analyses.  
Height (cm) and weight (kg) measured at age 43 years were used in analyses. 
 
Symptom and smoking definitions: 
The MRC respiratory questionnaire-based definition of chronic bronchitis (16-18), used to 
detect chronic sputum expectoration, has been validated against daily sputum volume 
production (31) and is considered unbiased by observer, season or administration method 
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(32).  The questionnaire includes separate questions about chronic cough.  “Chronic” refers 
to “at least three months yearly”.  At each time-point members could report chronic sputum 
expectoration, chronic cough, chronic cough with concurrent chronic sputum expectoration 
or no symptoms.  CMH was defined as chronic cough with chronic sputum expectoration.  
Those smoking at least one cigarette regularly for at least one year were considered 
smokers.  Smoking status refers to smoking activity at a given time-point (active, never or 
ex-smoker).  Active-smokers were those currently smoking.  Never-smokers consistently 
denied ever regularly smoking throughout the study. Ex-smokers were those who had 
smoked previously but were not currently smoking.  Cigarette consumption at each age was 
defined as the number of cigarettes currently smoked per day.   
 
Statistical analysis 
Symptom and smoking patterns across adult life 
Amongst those providing complete data on both symptoms and smoking behaviour at all six 
ages we calculated the percentage reporting symptoms and active-smoking at each age and 
at any age (i.e. ever-smokers, ever-CMH, ever-chronic sputum and ever-chronic cough).  
Differences in ever-CMH presence by ever-smoking status, were assessed using Chi-square 
tests.  Amongst the ever-CMH sample, CMH presence at each age was classified according 
to current and previous symptom reporting as follows: “not yet” (no current/previous 
CMH); “incident” (first report of CMH); “ongoing” (persistent CMH since the incident 
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report); “remission” (CMH reported previously but absent currently) and “relapse” (CMH 
currently reported following previous remission). 
 
Relationship between symptoms and smoking with age 
We investigated how CMH prevalence changed with concurrent smoking behaviour during 
each of the five consecutive time-periods between the six data collections.  For the period 
from 20 to 25 years, those with complete data at both ages and classified as either 
persistent-smokers (smoking at the start and end of the period), quitters (smoking at the 
start but not the end of the period) or never-smokers were included.   Similar analyses were 
carried out for the 4 subsequent periods with quitters being excluded from subsequent 
periods.  Chi-square tests were used to assess differences in CMH prevalence between 
smoking groups at beginning and end of each period.  McNemar’s tests were used to 
analyse change in CMH prevalence within each smoking group.  Separately, we repeated 
these analyses to investigate how chronic sputum expectoration prevalence and chronic 
cough prevalence changed over the five time periods.  
To explore how changing symptom prevalence amongst persistent-smokers might reflect 
changing cigarette consumption, Wilcoxon signed rank tests were used to test whether their 
cigarette consumption changed during each period.  Mann-Whitney U tests were used to 
analyse differences in cigarette consumption at the start of each period between quitters 
and persistent-smokers.  
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The relationship between symptoms across adult life and airflow limitation at age 60-64 
years  
Airflow limitation was defined as FEV1/FVC<lower limit of normal for their age (33), as 
recommended for epidemiological studies (34).  Multivariable logistic regression analyses 
were used to assess the relationship between being symptomatic (reporting chronic cough 
and/or chronic sputum expectoration) at each age amongst active and non-smokers and the 
presence of airflow limitation at age 60-64 years with adjustment for sex and concurrent 
cigarette consumption.  We tested for interactions between being symptomatic and both 
smoking status and cigarette consumption in order to determine whether associations 
between being symptomatic and airflow limitation were modified by smoking behaviour.  
Although the fixed ratio definition of airflow limitation (FEV1/FVC<0.70) is likely to over 
detect airflow limitation at 60-64 years (34), we repeated our analyses using this widely 
used definition. 
The relationship between CMH presence and concurrent FEV1 decline 
The relationship between CMH presence and concurrent FEV1 decline across ages 43, 53 and 
60-64 years was analysed using multilevel models which account for repeated measures on 
the same individual.  Random effects for both intercept and slope were included allowing 
individual intercepts and slopes to vary. We employed three approaches to representing 
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symptom presence: (1) dichotomising the population according to CMH presence at age 43 
years (present vs absent); (2) dichotomising the population according to CMH presence 
between ages 43 and 60-64 years (present ≥ once vs never-present); (3) for each individual 
calculating the duration of CMH by scoring the number of occasions on which they reported 
CMH across ages 43, 53 and 60-64 years (CMH duration score across the three time-points 
between 0 and 3).   
First, FEV1 change with age was modelled with both intercept and rate of change being 
allowed to vary according to sex, the intercept representing FEV1 at age 43 years.   All 
models were adjusted for both height and weight at 43 years of age.  Both intercept and 
slope were then allowed to vary according to CMH presence.  The CMH duration score was 
first fitted as a categorical variable and a test for linear trend carried out by fitting as a 
continuous variable.  Smoking status and cigarette consumption were included as time-
varying covariates and were allowed to influence both intercept and slope.  Results from 
these models were used to plot estimated FEV1 decline between ages 43 and 60-64 years 
amongst men and woman of average height and weight. 
Separately, we repeated these analyses to investigate the respective relationships between 
chronic sputum expectoration presence and then chronic cough presence with concurrent 
FEV1 decline across ages 43, 53 and 60-64 years. 
Analyses were carried out using SPSS version 22 (IBM Corporation, Armonk, NY, USA), and 
STATA version 14 (Stata Corporation, Texas, USA).  All tests were two sided and P<0.05 was 
considered statistically significant. 
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RESULTS: (Further data tables and figures are available in the online supplement) 
From the 5362 individuals initially enrolled within the cohort, 4427 (52% male, 63% ever-
smokers) provided symptom and smoking data at one or more occasions (Figure 1).   
 
Symptom and smoking patterns across adult life 
Of these 4427 individuals 1284 (46% male, 56% ever-smokers) contributed complete data at 
all time-points amongst whom 350 individuals (27.3%) reported chronic sputum (CS) or 
chronic cough (CC) at least once.  Most of those who reported chronic sputum had also 
reported chronic cough and vice versa (Figure 2A).  156 individuals (12.1%) reported CMH 
(chronic cough concurrent with chronic sputum expectoration) at least once.  Symptoms 
were more common amongst the 561 (43.7%) ever-smokers than the 723 (56.3%) never-
smokers (Figures 2A & 2B).  Although active-smoking declined between ages 20 and 60-64 
years (from 37.0% to 9.8%), CMH, chronic sputum expectoration and chronic cough 
prevalence increased (Figure 2C).  Figure 3 shows how CMH followed a remitting-relapsing 
course with at least 50% of the ever-CMH reporting population in symptom remission by 
age 60-64 years.  Figure E1 in the online supplement displays similar separate plots of 
chronic sputum expectoration presence and chronic cough presence data. 
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Relationship between symptoms and smoking with age  
CMH was more common amongst persistent-smokers than amongst never-smokers 
(p<0.001 at each age).  Figure 4 shows that amongst smokers, CMH prevalence rose 
between ages 36 and 43 years (p<0.001) and again between 53 and 60-64 years (p=0.008).  
CMH prevalence amongst never-smokers during these periods did not significantly change.  
Figure E2 (online supplement) shows similar plots for chronic sputum expectoration 
prevalence and chronic cough prevalence.  Chronic cough amongst smokers began to rise in 
prevalence between 20 and 25 years (p=0.002), whereas chronic sputum expectoration did 
not start to increase until between 36 and 43 years (p<0.001).  
In most time periods, smoking cessation was accompanied by CMH prevalence returning to 
levels seen amongst never-smokers, avoiding and/or reversing the symptom prevalence 
rises experienced by persistent-smokers (Figure 4).  Symptom onset and remission was also 
detected in the absence of changes in smoking behaviour with symptom prevalence trends 
across each period reflecting the balance between symptom onset and resolution rates 
(Figure E3, online supplement).  For example, relative to never-smokers, rising persistent-
smoker symptom prevalence reflected more frequent symptom onset and/or less frequent 
symptom resolution.  Figure 4 also shows that although smoking cigarette consumption 
increased until age 36 years, cigarette consumption then plateaued and, from age 42 years 
onwards actually decreased.   Furthermore, the dose-response relationship between 
cigarette consumption and symptom prevalence may steepen with advancing age (Figure 
E4, online supplement). 
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The relationship between chronic symptoms across adult life and airflow limitation at age 
60-64 years  
1137 individuals provided both reproducible FEV1 and FVC measurements at age 60-64 
years (42% male, 61% ever-smokers).  Airflow limitation was observed in 69 individuals 
(6.1%) at age 60-64, more commonly amongst ever-smokers (8.1%) than never-smokers 
(2.9%) (p<0.001).  81.2% of those with airflow limitation were ever-smokers.  Figure E5 
(online supplement) demonstrates how cumulative prevalence of chronic symptoms by age 
60-64 was greater amongst those with airflow limitation (56.7% 95%CI 44.1-69.2%) than 
those without (27.2% 95%CI 24.2 to 30.0%) but that only 28.3% (95% CI 16.9 to 39.7%) of 
those with airflow limitation still reported chronic symptom presence at this age.     
In adjusted models, symptom presence (relative to symptom absence) at ages 36 or 43 
years amongst active-smokers was associated with a significantly higher odds ratio of having 
airflow limitation by age 60-64, but symptom presence at ages 20, 25, 53 or 60-64 was not 
(Figure 5).   In contrast, amongst non-smokers, symptoms at most ages, which were rarer 
than amongst active-smokers and presumably due to other conditions or environmental 
factors, were associated with airflow limitation at age 60-64 years (Figure 5).  There was a 
suggestion that the association between symptom presence at age 20 and airflow limitation 
was stronger in non-smokers than smokers although the test for interaction (p=0.07) did not 
quite reach the conventional 5% significance level. There was no evidence of any interaction 
between smoking status and symptom presence at any of the later ages.    
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After separating non-smokers into never and ex-smokers (Figure E6, online supplement) we 
found no association between symptoms amongst ex-smokers and airflow limitation. The 
interaction between symptoms and smoking status (active versus never-smoker) at age 20 
was stronger (P=0.02) than when never and ex-smokers were grouped together, never-
smokers showing a much stronger association than current smokers. 
Results similar to those in Figure 5 were obtained using the FEV1/FVC<0.70 definition of 
airflow limitation (Figure E7, online supplement). 
 
The relationship between CMH presence and concurrent FEV1 decline 
1960 individuals who provided reproducible FEV1 measurements on at least one occasion 
contributed to each multilevel model (46% male; 59% ever-smoker).  There was no 
difference in participation rates at the home visit at 43 years by prior symptom reporting 
(Table E8), but those reporting symptoms from 36 years onwards were less likely to 
participate at 60-64 years (Table E8).  Mean FEV1 at age 43 years = 3.00 litres with overall 
FEV1 decline of 24.2 ml/year (95%CI 23.1 to 25.4 ml/year) in a model including only age.  
Addition of smoking status demonstrated that FEV1 declined more rapidly amongst smokers 
(31.7 ml/year 95%CI: 27.2 to 36.4 ml/year) than amongst non-smokers (23.2ml/year 95%CI: 
21.9-24.4 ml/year) (p<0.001).   
Inclusion of cigarette consumption in addition to smoking status did not alter the results of 
the multilevel models and was not included in the final models.  CMH presence at age 43 
years in fully adjusted models was associated with lower FEV1 but not accelerated FEV1 
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decline between ages 43 and 60-64 years (Table E6A, online supplement).   Widening the 
CMH presence classification to reflect CMH presence at ages 43, 53 or 60-64 years identified 
a larger symptomatic group (Table E5, online supplement) and this phenotype was also 
associated with both lower FEV1 and accelerated FEV1 decline (Table E6B, online 
supplement).  For example, reporting of CMH on at least one occasion between 43 and 60-
64 years was associated with an additional 4.5 ml/year decline in FEV1 in fully adjusted 
models (P=0.03). 
A linear relationship between FEV1 slope and CMH duration score fitted as a categorical 
variable was observed and thus duration score was subsequently included as a continuous 
variable.  CMH duration score was associated with both a lower FEV1 and faster FEV1 decline 
(Table 1).  For example, for each additional occasion CMH was reported there was an 
additional 3.6 ml/yr decline in FEV1 (p=0.005) i.e. presence of CMH on all three occasions 
was associated with an additional 10.8 ml/year FEV1 decline between ages 43 and 60-64 
years compared to those without CMH on any occasion.  Figure 6 shows this estimated FEV1 
decline according to CMH duration between ages 43 and 60-64 years calculated for males 
and females of average height and weight at age 43.   
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DISCUSSION 
 
This study demonstrates for the first time that middle-age amongst smokers is a period 
when chronic mucus hypersecretion (CMH) increasingly develops and when chronic 
symptoms can identify those at greater risk of having airflow limitation by their early sixties.  
Furthermore, this study shows that CMH followed a dynamic course across adult life.  
Smoking cessation at any age reversed or avoided the escalating prevalence of smoking-
related CMH.  We also show that the longer that CMH was present, the faster the decline in 
FEV1. 
It is well recognised that CMH is associated with smoking-related respiratory disease 
outcomes (1, 5-9, 35, 36), but how CMH develops and how its association with these health 
outcomes emerges over the adult life course, although much hypothesised, is little 
reported.  The NSHD is the first study to provide prospective, longitudinal symptom 
prevalence data using a validated questionnaire over such an extensive period of life within 
a nationally representative population.  Unlike many previous longitudinal studies, our study 
sample included both men and women (1, 3) from both rural and urban areas (1, 3, 37) who 
were recruited following birth within the same week in March 1946, making it more 
generalizable and removing the need to adjust for recruitment-bias towards symptomatic 
participants (1) or unequal participant age (7, 37).  
CMH symptoms are known to be more common amongst smokers (1, 4, 37, 38) and to 
become increasingly common with age (1, 12), but this study also demonstrates that the 
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relationship between symptoms and smoking evolves with age.  In contrast to the 
consistent and relatively low-level of CMH we found amongst never-smokers, CMH amongst 
smokers began to increase significantly between the ages of 36 and 43 years and increased 
further between 53 and 60 to 64 years.  The escalating symptom prevalence we found 
amongst smokers during middle-age was unlikely to be explained by rising cigarette 
consumption, which plateaued between 36 and 43 years before subsequently decreasing.  
Instead, these results may indicate a rising sensitivity to the effects of active-smoking during 
middle-age, possibly reflecting an evolving physiological response accompanying ageing (39-
41) and/or the unmasking of underlying susceptibility to the effects of smoking following 
sufficient exposure. 
The extent to which smoking-related symptoms predict future COPD development, often 
identified by airflow limitation presence (42), has long been debated (1, 4, 10, 11, 13, 43).  
We found this relationship varied according to the age of symptom reporting.  In contrast to 
symptoms at ages 20 or 25 years, the presence of symptoms at age 36 or 43 years identified 
active-smokers at higher risk of having airflow limitation by their early sixties.  This finding 
taken together with the rises in symptom prevalence seen amongst smokers suggests that 
middle-age is an important early phase in COPD development.   
In common with others monitoring symptoms over time (1-3, 7, 10, 13, 37), we found that 
the reporting of CMH symptoms followed a dynamic course with changing prevalence 
reflecting an imbalance between rates of symptom onset and remission (2).  Smoking 
cessation, as previously reported (2), was associated with more frequent disappearance and 
less frequent appearance of symptoms, resulting in lower symptom prevalence compared to 
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persistent-smokers (2, 38).  However, we also show that symptom prevalence actually 
returned to that of never-smokers following smoking cessation at most ages, even when 
cessation occurred in the fifth or sixth decades of life.  These findings therefore highlight 
both the strong relationship between active-smoking and symptoms and the scope to 
alleviate and/or avoid respiratory symptoms at any age through smoking cessation.   
Although CMH is classically considered a binary phenotype (44), within this longitudinal 
study, CMH presence at 60 to 64 years identified only 50% of those who had reported CMH 
during adult life.  The evident instability of CMH across adult life may prompt a re-
evaluation of studies which characterise subjects based upon CMH presence later in adult 
life and/or at a single time-point.  For example, amongst those without CMH symptoms later 
in life, the presence of airflow limitation may instead relate to a symptomatic phase earlier 
in life which has subsequently abated.  With advancing age, an increasing proportion of our 
study sample entered symptom remission whilst the time remaining for airflow limitation 
development decreased.  Together these observations might explain why, similar to Guerra 
et al (11), we found symptom presence later in life poorly identify those smokers at greater 
risk of having airflow limitation by age 60 to 64 years compared to the same symptoms at 
earlier ages.   
This study also suggests that the course of CMH is clinically relevant to lung function decline 
and potentially disease development.  Some have already suggested the association 
between CMH and poor respiratory outcomes is clearest amongst those with persistent 
CMH (7, 10), but this is the first study to suggest that the longer CMH is present the greater 
the concurrent FEV1 decline, even after adjusting for smoking behaviour.  Although smoking 
Page 20 of 60 AJRCCM Articles in Press. Published on 22-December-2015 as 10.1164/rccm.201511-2210OC 
 Copyright © 2015 by the American Thoracic Society 
19 
 
cessation may reduce airway inflammation (45), several studies of ex-smokers, 
predominantly those still reporting CMH, show airway inflammation can persist (45-47).  
These studies are small in size and are usually cross-sectional or short in duration.  However, 
their findings infer that CMH presence indicates heightened airway inflammation and may 
reflect active disease.  Hypothetically, the changes in CMH presence we demonstrate could 
indicate changing airway disease activity either in response to changing environmental 
exposure and/or altered physiological response to such insults.  Investigating how the 
presence of airway inflammation, associated with CMH (7, 47, 48), changes according to the 
appearance, persistence and disappearance of CMH may help identify novel biomarkers 
useful in research or to guide therapeutic interventions. 
Within our study, FEV1 decline appeared most prominent amongst those concurrently 
reporting chronic cough and chronic sputum expectoration.  A varying association between 
different symptom complexes and FEV1 decline may partly explain conflicting outcomes 
from studies using the chronic productive cough (7) rather than the chronic sputum 
expectoration (1) definition of CMH.  Chronic cough and chronic sputum expectoration may 
represent different pathophysiological responses to smoking and their co-existence, which 
is associated with higher respiratory-cause mortality (20), may represent a particularly 
intense smoking-response. However, less than half of those reporting either chronic cough 
or chronic sputum expectoration during this study reported both symptoms concurrently.  
Therefore, although the chronic productive cough definition of CMH probably identifies 
those responding particularly intensely to smoking exposure, it also leaves a considerable 
number of smokers experiencing abnormal chronic symptoms undetected and unstudied.  
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A limitation of this study, as with all symptom-based studies, is its reliance upon self-
reporting and therefore misreporting may contribute to changing symptom status.  We 
consistently used the extensively validated MRC questionnaire which is one of the best tools 
available for accurate symptom detection on this scale.  Symptoms amongst some 
individuals, particularly amongst our never-smoker sample, may be the result of 
environmental exposures, such as pollution, or diseases unrelated to smoking, such as 
asthma (49, 50).     Chronic symptoms amongst asthmatics can indicate poor asthma control 
(50) perhaps partly explaining their association with subsequent airflow limitation within the 
small sub-sample of never-smokers reporting symptoms during this study.  One of the 
merits, however, of this study is that we examined a sample representative of native born 
British men and women of the same age who were enrolled at birth (28) and this avoided 
potential sample bias due to inaccurate self-reported medical conditions based upon 
unverifiable prior symptom interpretation (51).  This study highlights the need for further 
research to ascertain why chronic symptoms develop amongst some individuals but not 
others and the role of asthma remains a key area of interest.    
A major strength of this study is that participants were followed for a long period of time 
spanning the majority of adult life but this also introduces several limitations.   Firstly, our 
study sample is predominantly Caucasian, being representative of those born in England, 
Scotland and Wales in one week in March 1946, potentially affecting the applicability of our 
findings to other ethnic populations.  Secondly, the NSHD protocol was designed prior to 
publication of guidelines promoting post-bronchodilator spirometry measurements 
potentially leading to over detection of airflow limitation within this study sample.   Finally, 
longer studies inevitably offer more opportunity for participant loss over time potentially 
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introducing follow-up bias, for example, with the loss of sicker individuals.  Although the 
NSHD study sample appears to have remained broadly nationally representative (28), we 
found symptomatic individuals were more likely to have left the study at age 60-64 and 
hence we may have underestimated the association between symptoms and lung function 
decline.    
In summary, during middle-age, CMH prevalence amongst smokers escalates and a 
relationship emerges between symptoms and the subsequent presence of airflow limitation.   
These changes potentially represent an early phase of COPD development.  Furthermore, 
the escalating chronic symptom prevalence experienced by smokers is avoided and reversed 
through smoking cessation at any age, emphasising the benefits of stopping smoking 
irrespective of life stage.  CMH is traditionally regarded as a phenotype associated with poor 
clinical outcomes and whilst this may be true, during life CMH appears and disappears.  The 
duration of CMH also appears to be related to the concurrent rate of FEV1 decline 
independent of smoking behaviour.  Therefore the course of CMH may reflect the 
underlying course of airway disease activity and be a marker of COPD development.  
Longitudinal studies of the inflammatory and physiological characteristics accompanying 
different chronic symptom courses amongst smokers, particularly in early adult life, are 
warranted to advance our understanding of how airway disease develops ultimately aiming 
to facilitate both early detection and intervention.  
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Figure Legends: 
 
 
FIGURE 1:  
Timeline of cohort size and data collection during the study between recruitment in 1946 
and the most recent data collection in 2006-2011 
 
 
 
FIGURE 2:   
The prevalence of Chronic Mucus Hypersecretion (CMH), Chronic Sputum expectoration 
(CS), Chronic Cough (CC) and cigarette smoking amongst those individuals providing 
complete data at all six time-points within the NSHD (n=1284).  (A) Area proportional Venn 
diagram (52) representing the overlapping cumulative prevalence (%) of CS (Ever-CS), CC 
(Ever-CC) and cigarette smoking (Ever-smoker vs Never-smoker).  Numbers shown are 
percentages of the included population (n=1284). (B) Analysis of differences in cumulative-
symptom prevalence between Ever and Never-smoker groups (p values calculated using Chi-
Square test).  (C)  Prevalence (%) with 95% Confidence Interval of CMH, CS, CC and cigarette 
smoking at each of six time-points between 1966 and 2009. 
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FIGURE 3:   
The longitudinal pattern of Chronic Mucus Hypersecretion (CMH) presence amongst those 
providing complete data at all six NSHD time-points (n=1284) and reporting CMH on at 
least one occasion (156 individuals, 12.1%).  At each time-point individuals are classified 
according to their previous and current reporting of CMH as follows (and in the CMH 
presence classification box): “not yet” (no current/previous CMH); “incident” (first report of 
CMH); “ongoing” (persistent CMH since the incident report); “remission” (CMH reported 
previously but absent currently) and “relapse” (CMH currently reported following previous 
remission).  CMH = chronic cough with concurrent chronic mucus expectoration.  Figure E1 
in the online supplement displays similar separate plots of chronic sputum expectoration 
presence and chronic cough presence data. 
 
 
FIGURE 4:   
The prevalence of Chronic Mucus Hypersecretion (CMH) (with 95% Confidence Intervals) 
and median smoking cigarette consumption during five time-periods over adult life within 
the NSHD according to concurrent cigarette smoking behaviour (Additionally, see Figures 
E2-3 and Tables E2-4 in the online supplement)   
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FIGURE 5:   
The relationship between chronic symptoms (chronic cough and/or chronic sputum 
expectoration) amongst smokers and non-smokers at different ages during adult life and 
the presence of airflow limitation (FEV1/FVC < lower limit of normal) by age 60-64 years.  
Logistic regression models adjusted for sex, concurrent smoking cigarette consumption.  The 
log odds ratio (95% CIs) of having developed airflow limitation by the time they reached 60-
64 years of age amongst those with chronic symptoms at each age.  
 
 
FIGURE 6:  
The influence of duration of Chronic Mucus Hypersecretion (CMH) presence on FEV1 
decline between ages 43 and 60-64 years.   
Estimated FEV1 decline between 43 and 60-64 years of age calculated using multilevel 
models (Table 1) including average height and weight for (A) males (height 176cm; weight 
79kg); and (B) females (height 163cm; weight 66kg) according to the number of occasions 
CMH was reported across the three time-points. 
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Coefficient (95% CI) p value Coefficient (95% CI) p value
Constant -2328.2 (-2840.4  to  -1815.9) - -22.3 (-23.9  to  -20.8) <0.001
Height (cm) at age 43 years 31.8 (28.5  to  35.1) <0.001 - - -
Weight (Kg) at age 43 years -3.2 (-5.0  to  -1.5) <0.001 - - -
Male Sex 574.9 (515.5  to  634.3) <0.001 -1.4 (-3.6  to  0.9) 0.24
Cigarette smoking -22.0 (-62.5  to  18.5) 0.29 -7.5 (-10.8  to  -4.3) <0.001
Per occasion                                                
chronic cough with chronic sputum 
reported between ages                                                         
43 and (60-64) years                                      
(0 - 3 occasions)
-162.3 (-208.5  to  -116.1) <0.001 -3.6 (-6.1  to  -1.1) 0.005
FEV1 intercept (ml) at age 43 years
FEV1 linear change per year (ml/year) between ages 43 
and 60-64 years
 
Tables 
TABLE 1: 
The influence of duration of Chronic Mucus Hypersecretion (CMH) presence on multilevel 
models estimating the relationship between CMH presence and concurrent FEV1 decline 
between ages 43 and 60-64 years.  Multilevel modelling included 1960 men and woman.  
Mean FEV1 at age 43 years was 3.00 litres, with an unadjusted FEV1 decline of 24.2 ml/year.  
Coefficients are adjusted for sex, height at age 43 years, weight at age 43 years and smoking 
status.  Duration of CMH is represented by the number of occasions CMH was reported over 
the three time-points (between zero and three occasions) (Online supplement: Table E6 
displays the results of separate modelling of chronic sputum expectoration and chronic 
cough presence). 
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Figure E1   
The longitudinal pattern of symptom presence 
amongst those providing complete data at all six 
NSHD time-points (n=1284) and reporting that 
symptom to be present on at least one occasion.  
At each time-point individuals are classified 
according to their previous and current reporting of 
respective symptom(s) as follows (and in the 
symptoms classification box): “not yet” (no 
current/previous); “incident” (first report of 
symptoms); “ongoing” (persistent since the 
incident report); “remission” (reported previously 
but absent currently) and “relapse” (currently 
reported following previous remission).  A: Chronic 
Sputum (CS) presence amongst 222 individuals 
(17.3%) reporting CS on at least one occasion.  B: 
Chronic Cough (CC) presence amongst the 22.7% 
(291 individuals) reporting CC on at least one 
occasion.  C: Chronic Sputum with concurrent 
Chronic Cough (CC&CS) presence amongst the 
12.1% (156 individuals) reporting CC&CS on at least 
one occasion. 
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Figure E2 The prevalence of Chronic Sputum (CS), Chronic Cough (CC) and Chronic Sputum 
with concurrent Chronic Cough (CC&CS) (with 95% Confidence Intervals) and median 
smoking intensity during five time-periods over adult life within the NSHD according to 
concurrent cigarette smoking behaviour (Tables E2-4 and Figure E3).   
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Figure E3   
The prevalence of (A) Chronic Sputum (CS), (B) Chronic Cough (CC) and (C) Chronic Sputum 
with concurrent Chronic Cough (CC&CS)  (with 95% Confidence Intervals) during five time-
periods over adult life within the NSHD according to concurrent cigarette smoking 
behaviour and according to the presence or absence of respective symptom(s) at the start 
of the period (Tables S7-S12).  CS+, CC+ and CC&CS+ denote presence of respective 
symptom; CS-, CC- and CC&CS- denote absence of respective symptom.  See Figure 4. 
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Figure E4 
The prevalence pattern of Chronic Sputum (CS), Chronic Cough (CC) and Chronic Cough 
concurrent with concurrent Chronic Sputum (CC&CS) according to intensity of smoking 
(number of cigarettes smoked daily) at different ages during adult life within the NSHD. 
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Figure E5 
The presence of chronic cough and/or chronic sputum expectoration (CC/CS) during adult 
life amongst those with and without airflow limitation (FEV1/FVC < lower limit of normal) 
by age 60-64 years. 
(A) Prevalence and cumulative prevalence of CC/CS amongst those 1137 individuals 
providing complete data at ≥ one time-point and with lung function data at age 60-64 years 
(those included in Figure 5); (B) Prevalence and cumulative prevalence of CC/CS amongst 
those 582 individuals providing complete data at all time-points and with lung function data 
at age 60-64 years.  Prevalence or cumulative prevalence is represented as a percentage 
with 95% confidence intervals. 
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Figure E6 
The relationship between chronic symptoms (chronic cough and/or chronic sputum 
expectoration) amongst smokers, ex-smokers and never-smokers at different ages during 
adult life and the prevalence of airflow limitation (FEV1/FVC < lower limit of normal) by 
age 60-64 years. Logistic regression models adjusted for sex, concurrent smoking cigarette 
consumption. The log odds ratio (95% CIs) of having developed airflow limitation by the time 
they reached 60-64 years of age amongst those with chronic symptoms at each age.  A small 
number of individuals included in Figure 5 are excluded from this analysis as not all non-
smokers could be classified as ex-smokers or never-smokers (for example, they subsequently 
started smoking for the first time). 
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Figure E7 
The relationship between chronic symptoms (chronic cough and/or chronic sputum 
expectoration) amongst smokers and non-smokers at different ages during adult life and 
the presence of FEV1/FVC<0.70 by age 60-64 years.  FEV1/FVC<0.70 was present in 107 
(9.4%) of the 1137 individuals included, more commonly amongst ever-smokers (11.3%) 
than amongst never-smokers (6.5%) (p=0.007).  72.9% of those with FEV1/FVC<0.70 were 
ever-smokers.  Logistic regression models adjusted for sex, concurrent smoking cigarette 
consumption. The log odds ratio (95% CIs) of having developed an FEV1/FVC ratio <0.70 by 
the time they reached 60-64 years of age amongst those with chronic symptoms at each 
age. 
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Table E1 
Number of times symptom(s) (Chronic Sputum (CS), Chronic Cough (CC) or CC with 
concurrent CS (CC&CS)) reported across six time-points by cohort members who provided 
complete data at all six time-points (n=1284) and reported respective symptom(s) at least 
once. 
 
 
 
 
 
 
 
Count % Count % Count %
1 136 61.3 172 59.1 99 63.5
2 42 18.9 58 19.9 26 16.7
3 24 10.8 23 7.9 20 12.8
4 7 3.2 25 8.6 4 2.6
5 11 5.0 6 2.1 6 3.8
6 2 0.9 7 2.4 1 0.6
Total 222 100.0 291 100.0 156 100.0
Number of times 
symptom reported 
by subjects across 
six time-points
SYMPTOM(S)
Group reporting CS at least 
once during the study                           
(n=222)
Group reporting CC at least 
once during the study                         
(n=291)
Group reporting CS with CC 
at least once during the 
study (n=156)
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Table E2 
The prevalence of Chronic Sputum (CS) (with 95% Confidence Intervals) during five time-
periods over adult life within the NSHD according to concurrent cigarette smoking 
behaviour.  Chi-square tests were used to assess differences in CS prevalence between 
smoking groups at beginning and end of each period.  McNemar’s tests were used to 
analyse change in CS prevalence within each smoking group (Figure 4).  
 
 
 
Persistent    
vs             
Never 
Smoker
Persistent 
Smoker            
vs               
Quitter 
Quitter           
vs               
Never 
Smoker
Persistent    
vs             
Never 
Smoker
Persistent 
Smoker            
vs               
Quitter 
Quitter           
vs               
Never 
Smoker
Persistent-Smoker (n=878) 7.3 (5.6 to 9.0) 7.7 (6.0 to 9.5) 0.75
Quitter (n=224) 4.0 (1.4 to 6.6) 4.5 (1.8 to 7.2) 1
Never-Smoker (n=982) 3.1 (2 to 4.1) 2.1 (1.2 to 3.0) 0.18
Persistent-Smoker (n=651) 8.6 (6.4 to 10.8) 8.0 (5.9 to 10.1) 0.73
Quitter (n=307) 3.6 (1.5 to 5.7) 2.3 (0.6 to 3.9) 0.39
Never-Smoker (n=857) 2.7 (1.6 to 3.8) 3.4 (2.2 to 4.6) 0.41
Persistent-Smoker (n=667) 9.9 (7.6 to 12.2) 16.8 (14 to 19.6) <0.001
Quitter (n=199) 6.5 (3.1 to 10.0) 4.5 (1.6 to 7.4) 0.42
Never-Smoker (n=1053) 2.9 (1.9 to 4.0) 3.7 (2.6 to 4.8) 0.28
Persistent-Smoker (n=481) 15.2 (12 to 18.4) 17.7 (14.3 to 21.1) 0.22
Quitter (n=173) 17.3 (11.7 to 23) 6.9 (3.2 to 10.7) 0.001
Never-Smoker (n=1033) 3.5 (2.4 to 4.6) 3.9 (2.7 to 5.0) 0.64
Persistent-Smoker (n=204) 19.1 (13.7 to 24.5) 28.4 (22.2 to 34.6) 0.008
Quitter (n=137) 13.1 (7.5 to 18.8) 9.5 (4.6 to 14.4) 0.33
Never Smoker (n=866) 4.0 (2.7 to 5.4) 6.9 (5.2 to 8.6) 0.002
BEGINNING OF PERIOD
Classification of 
smoking behaviour 
during period 1 
(1966-1971)  
(n=2084)
Prevalence of 
Chronic Sputum 
(CS) (%)
95%CI
Chi-square test
Prevalence of 
Chronic Sputum 
(CS) (%)
95%CI
Chi-square test
END OF PERIOD
Significance of change 
in prevalence between 
beginning and end of 
period (McNemar's 
test)
0.46 <0.001 0.08 0.04
Classification of 
smoking behaviour 
during period 2 
(1971-1982)  
(n=1815)
<0.001 0.004 0.42
<0.001 0.08
Classification of 
smoking behaviour 
during period 3 
(1982-1989)  
(n=1919)
<0.001 0.15 0.01 <0.001
<0.001 <0.001 0.33
Classification of 
smoking behaviour 
during period 4 
(1989-1999)  
(n=1687)
<0.001 0.50 <0.001
<0.001 0.58
Classification of 
smoking behaviour 
during period 5 
(1999-(2006-2011))  
(n=1207)
<0.001 0.15 <0.001 <0.001
<0.001 <0.001 0.06
<0.001 0.28
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Table E3 
 The prevalence of Chronic Cough (CC) (with 95% Confidence Intervals) during five time-
periods over adult life within the NSHD according to concurrent cigarette smoking 
behaviour.  Chi-square tests were used to assess differences in CC prevalence between 
smoking groups at beginning and end of each period.  McNemar’s tests were used to 
analyse change in CC prevalence within each smoking group (Figure 4). 
  
Persistent    
vs             
Never 
Smoker
Persistent 
Smoker            
vs               
Quitter 
Quitter           
vs               
Never 
Smoker
Persistent      
vs          
Never 
Smoker
Persistent 
Smoker            
vs               
Quitter 
Quitter           
vs          
Never 
Smoker
Persistent-Smoker (n=878) 8.8 (6.9 to 10.6) 12.8 (10.5 to 15) 0.002
Quitter (n=224) 3.6 (1.1 to 6.0) 3.1 (0.8 to 5.4) 1.00
Never Smoker (n=982) 2.7 (1.7 to 3.8) 3.1 (2.0 to 4.1) 0.72
Persistent-Smoker (n=651) 13.5 (10.9 to 16.1) 14.9 (12.2 to 17.6) 0.46
Quitter (n=307) 6.2 (3.5 to 8.9) 4.2 (2.0 to 6.5) 0.35
Never Smoker (n=857) 3.7 (2.5 to 5.0) 2.8 (1.7 to 3.9) 0.26
Persistent-Smoker (n=667) 16.5 (13.7 to 19.3) 24.0 (20.7 to 27.2) <0.001
Quitter (n=199) 10.6 (6.3 to 14.8) 4.0 (1.3 to 6.7) 0.002
Never Smoker (n=1053) 2.8 (1.8 to 3.7) 4.1 (2.9 to 5.3) 0.05
Persistent-Smoker (n=481) 21.4 (17.7 to 25.1) 27.7 (23.7 to 31.6) 0.003
Quitter (n=173) 23.7 (17.4 to 30) 8.1 (4.0 to 12.2) <0.001
Never Smoker (n=1033) 3.7 (2.5 to 4.8) 5.2 (3.9 to 6.6) 0.04
Persistent-Smoker (n=204) 27.0 (20.9 to 33.1) 34.3 (27.8 to 40.8) 0.06
Quitter (n=137) 20.4 (13.7 to 27.2) 10.9 (5.7 to 16.2) 0.03
Never Smoker (n=866) 5.0 (3.5 to 6.4) 8.5 (6.7 to 10.4) <0.001
Prevalence of 
Chronic Cough    
(CC) (%)
95%CI
BEGINNING OF PERIOD END OF PERIOD
Significance of change 
in prevalence between 
beginning and end of 
period (McNemar's 
test)
Chi-square test
Prevalence of 
Chronic Cough    
(CC) (%)
95%CI
Chi-square test
0.95
Classification of 
smoking behaviour 
during period 1 
(1966-1971)  
(n=2084)
<0.001 0.009 0.51 <0.001 <0.001
0.07 <0.001 <0.001 0.21
Classification of 
smoking behaviour 
during period 2 
(1971-1982)  
(n=1815)
<0.001 <0.001
<0.001 <0.001 0.96
Classification of 
smoking behaviour 
during period 3 
(1982-1989)  
(n=1919)
<0.001 0.04 <0.001
<0.001 <0.001 <0.001 0.13
Classification of 
smoking behaviour 
during period 4 
(1989-1999)  
(n=1687)
<0.001 0.53
<0.001 <0.001 0.35
Classification of 
smoking behaviour 
during period 5 
(1999-(2006-2011))  
(n=1207)
<0.001 0.17 <0.001
Page 53 of 60  AJRCCM Articles in Press. Published on 22-December-2015 as 10.1164/rccm.201511-2210OC 
 Copyright © 2015 by the American Thoracic Society 
15 
 
Persistent    
vs             
Never 
Smoker
Persistent 
Smoker            
vs               
Quitter 
Quitter           
vs               
Never 
Smoker
Persistent    
vs             
Never 
Smoker
Persistent 
Smoker            
vs               
Quitter 
Quitter           
vs               
Never 
Smoker
Persistent-Smoker (n=878) 4.9 (3.5 to 6.3) 5.1 (3.7 to 6.6) 0.90
Quitter (n=224) 1.8 (0.1 to 3.5) 2.7 (0.6 to 4.8) 0.73
Never Smoker (n=982) 1.4 (0.7 to 2.2) 1.1 (0.5 to 1.8) 0.63
Persistent-Smoker (n=651) 5.8 (4.0 to 7.6) 6.8 (4.8 to 8.7) 0.53
Quitter (n=307) 1.6 (0.2 to 3.0) 1.3 (0.0 to 2.6) 1
Never Smoker (n=857) 1.6 (0.8 to 2.5) 2.0 (1.1 to 2.9) 0.69
Persistent-Smoker (n=667) 7.6 (5.6 to 9.7) 13.0 (10.5 to 15.6) <0.001
Quitter (n=199) 5.5 (2.4 to 8.7) 2.5 (0.3 to 4.7) 0.07
Never Smoker (n=1053) 1.6 (0.9 to 2.4) 2.6 (1.6 to 3.5) 0.09
Persistent-Smoker (n=481) 11.4 (8.6 to 14.3) 14.1 (11 to 17.3) 0.14
Quitter (n=173) 13.3 (8.2 to 18.4) 5.8 (2.3 to 9.3) 0.007
Never Smoker (n=1033) 2.3 (1.4 to 3.2) 2.4 (1.5 to 3.4) 1
Persistent-Smoker (n=204) 14.2 (9.4 to 19.0) 22.5 (16.8 to 28.3) 0.008
Quitter (n=137) 8.8 (4.0 to 13.5) 4.4 (1.0 to 7.8) 0.15
Never Smoker (n=866) 2.7 (1.6 to 3.7) 4.0 (2.7 to 5.4) 0.06
<0.001 <0.001 0.85
Classification of 
smoking behaviour 
during period 5 
(1999-(2006-2011))  
(n=1207)
<0.001 0.13
Classification of 
smoking behaviour 
during period 4 
(1989-1999)  
(n=1687)
<0.001
<0.001
0.96
Classification of 
smoking behaviour 
during period 3 
(1982-1989)  
(n=1919)
<0.001 0.31
0.52 <0.001 <0.001 0.004 0.01
1.00 <0.001 <0.001 0.44
Classification of 
smoking behaviour 
during period 2 
(1971-1982)  
(n=1815)
<0.001
<0.001 <0.001 <0.001
0.07
Classification of 
smoking behaviour 
during period 1 
(1966-1971)  
(n=2084)
<0.001 0.04 0.69 <0.001
0.003
Prevalence of 
Chronic Cough 
with concurrent 
Chronic Sputum 
(CC&CS) (%)
95%CI
Chi-square test
Prevalence of 
Chronic Cough 
with concurrent 
Chronic Sputum 
(CC&CS) (%)
95%CI
0.12
Chi-square test
END OF PERIOD
Significance of change 
in prevalence between 
beginning and end of 
period (McNemar's 
test)
BEGINNING OF PERIOD
Table E4 
The prevalence of Chronic Cough with concurrent Chronic Sputum (CC&CS) (with 95% 
Confidence Intervals) during five time-periods over adult life within the NSHD according to 
concurrent cigarette smoking behaviour.  Chi-square tests were used to assess differences in 
CC&CS prevalence between smoking groups at beginning and end of each period.  
McNemar’s tests were used to analyse change in CC&CS prevalence within each smoking 
group (Figure 4). 
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CS CC CC&CS
102/1858 144/1816 75/1885
263/1697 352/1608 187/1773
0 1697 1608 1773
1 171 237 128
2 61 69 37
3 31 46 22
Symptom/Asymptomatic at age 43 years
Symptomatic ≥ once / Never-symptomatic                                                
between 43 & 60-64 years
Symptom duration                                                                             
(No. of occasions symptoms reported                                                                   
between ages 43 and 60-64 years)                                                                      
(0 - 3 occasions)
Symptom group
Table E5 
Classification of population sample included in multilevel modelling of FEV1 decline 
across three time-points (age 43, 53 and 60-64 years) according to concurrent symptom 
presence (See Table 1) as follows: (a) Symptomatic vs asymptomatic at age 43 years; (b) 
Symptomatic at least once vs never-symptomatic across ages 43, 53 and 60-64 years; 
(c) Symptom duration across ages 43, 53 and 60-64 years (scored between zero and 
three according to frequency of respective symptom reporting across the three time-
points).  CS=Chronic Sputum; CC=Chronic Cough; CC&CS=Chronic Cough with 
concurrent Chronic Sputum. 
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Table E6 
The influence of longitudinal symptom pattern on multilevel models estimating the 
relationship between symptom presence and concurrent FEV1 decline between ages 43 
and 60-64 years.  Multilevel modelling included 1960 men and woman.  Mean FEV1 at age 
43 years was 3.00 litres, with an unadjusted FEV1 decline of 24.2 ml/year.  Minimally 
adjusted coefficients are adjusted for sex.  Fully adjusted coefficients are adjusted for sex, 
height at age 43 years, weight at age 43 years and smoking status.  Presence of symptoms 
(CS=Chronic Sputum; CC=Chronic Cough; and CC&CS=Chronic Cough with concurrent 
Chronic Sputum) is represented as follows: (A) Symptomatic vs asymptomatic at age 43 
years; (B) Symptomatic at least once vs never-symptomatic across ages 43, 53 and 60-64 
years; (C) Symptom duration represented by the number of occasions that symptom was 
reported over the three time-points (between zero and three occasions).  See Table E5. 
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Coefficient (95% CI) p value Coefficient (95% CI) p value
Minimally adjusted† -344.7    (-449.0 to -240.5) <0.001 -2.6    (-7.8 to 2.6) 0.32
Fully adjusted‡ -336.6    (-434.3 to -238.9) <0.001 -2.2    (-7.4 to 3.0) 0.41
Minimally adjusted† -304.2    (-391.9 to -216.5) <0.001 -5.3    (-9.6 to -1.1) 0.01
Fully adjusted‡ -288.7    (-371.6 to -205.9) <0.001 -4.3    (-8.6 to 0.0) 0.05
Minimally adjusted† -389.1    (-510.0 to -268.1) <0.001 -3.7    (-9.7 to 2.4) 0.23
Fully adjusted‡ -390.1    (-503.0 to -277.3) <0.001 -3.3    (-9.4 to 2.7) 0.28
† Adjusted for sex and age
Coefficient (95% CI) p value Coefficient (95% CI) p value
Minimally adjusted† -205.3    (-273.3 to -137.2) <0.001 -5.0    (-8.3 to -1.7) 0.00
Fully adjusted‡ -206.1    (-270.0 to -142.2) <0.001 -4.1    (-7.4 to -0.7) 0.02
Minimally adjusted† -187.7    (-248.0 to -127.4) <0.001 -4.9    (-7.8 to -2.0) 0.00
Fully adjusted‡ -173.8    (-231.0 to -116.7) <0.001 -4.0    (-7.0 to -1.0) 0.01
Minimally adjusted† -231.3    (-310.3 to -152.3) <0.001 -5.5    (-9.3 to -1.6) 0.01
Fully adjusted‡ -235.9    (-310.0 to -161.9) <0.001 -4.5    (-8.4 to -0.7) 0.02
† Adjusted for sex and age
Coefficient (95% CI) p value Coefficient (95% CI) p value
CS Minimally adjusted† -145.9    (-187.5 to -104.3) <0.001 -3.7    (-5.7 to -1.6) 0.00
Fully adjusted‡ -149.0    (-188.1 to -109.9) <0.001 -3.2    (-5.3 to -1.1) 0.00
Minimally adjusted† -133.6    (-169.9 to -97.3) <0.001 -3.8    (-5.6 to -2.0) <0.001
Fully adjusted‡ -128.5    (-163.0 to -94.0) <0.001 -3.1    (-4.9 to -1.2) 0.00
Minimally adjusted† -156.6    (-205.9 to -107.4) <0.001 -4.3    (-6.8 to -1.8) 0.00
Fully adjusted‡ -162.3    (-208.5 to -116.1) <0.001 -3.6    (-6.1 to -1.1) 0.01
(A) Model including phenotyping based upon sympton reporting at age 43 years (n=1960)
FEV1 intercept (ml) at age 43 years
FEV1 linear change per year (ml/year) 
between ages 43 and 60-64 years
Symptom reported                                                
at age 43 years
CS
CC
CC&CS
CC
CC&CS
‡ Adjusted for sex, age, height at age 43 years, weight at age 43 years, smoking behaviour and smoking intensity at 
(B) Model including phenotyping based upon symptom reporting between 43 and 60-64 years (n=1960)
FEV1 intercept (ml) at age 43 years
FEV1 linear change per year (ml/year) 
between ages 43 and 60-64 years
Symptom reported                                                
≥ once between                                                        
43 & 60-64 years
CS
CC
CC&CS
† Adjusted for sex and age
‡ Adjusted for sex, age, height at age 43 years, weight at age 43 years and smoking status at ages 43, 53 and 60-64 years
‡ Adjusted for sex, age, height at age 43 years, weight at age 43 years, smoking behaviour and smoking intensity at 
(C) Model including duration score based upon symptom reporting between ages 43 and 60-64 years (n=1960)
FEV1 intercept (ml) at age 43 years
FEV1 linear change per year (ml/year) 
between ages 43 and 60-64 years
Per occasion 
symptom reported 
between ages                                                         
43 and 60-64 years                                      
(0 - 3 occasions)
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Table E7 
Participation of cohort members in surveys at age 43 and 60-64 years according to prior 
reporting of chronic symptoms at ages 20, 25, 36, 43 and 53 years of age.  (A) Chronic 
Sputum expectoration reporting; (B) Chronic Cough reporting; (C) Chronic Cough concurrent 
with Chronic Sputum expectoration reporting.  P values calculated using Chi-Square test.   
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Table E8 
The cumulative prevalence of Chronic Cough and/or Chronic Sputum Expectoration 
(CC/CC), Chronic Sputum Expectoration (CS), Chronic Cough (CC) and Chronic Productive 
Cough (CS&CC) by age 60-64 years according to the presence of airflow limitation 
(FEV1/FVC<Lower limit of normal) at age 60-64 years amongst the 1137 individuals 
included in Figure 5.  Cumulative prevalence of each symptom complex was higher amongst 
those with airflow limitation at age 60-64 years (p<0.001; Chi Square tests). 
 
 
 
 
 
 
 
 
 
 
Overall
Absent (n=1068) Present (n=69) (n=1137)
CC/CS 27.3 (24.7 to 30) 56.5* (44.8 to 68.2) 29.1 (26.5 to 31.8)
CS 16.5 (14.3 to 18.7) 34.8* (23.5 to 46) 17.6 (15.4 to 19.8)
CC 22.7 (20.1 to 25.2) 50.7* (38.9 to 62.5) 24.4 (21.9 to 26.9)
CC&CS 11 (9.2 to 12.9) 26.1* (15.7 to 36.4) 12 (10.1 to 13.8)
Cumulative                      
symptom prevalence                       
by age 60-64 years                           
% (95% CI)
Presence of airflow limitation at age 60-64 years 
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